Pfizer to Acquire Immuneering Corp.
Ticker: IMRX · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1790340
| Field | Detail |
|---|---|
| Company | Immuneering Corp (IMRX) |
| Form Type | 8-K |
| Filed Date | Jan 13, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $13.7 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, merger, biotech
TL;DR
Pfizer buying Immuneering for immunology pipeline. Deal expected H1 2025.
AI Summary
Immuneering Corp. announced on January 13, 2025, that it has entered into a definitive agreement to be acquired by Pfizer Inc. The transaction is expected to close in the first half of 2025, subject to customary closing conditions. This acquisition aims to enhance Pfizer's pipeline in immunology and inflammation.
Why It Matters
This acquisition by a major pharmaceutical company like Pfizer could significantly impact Immuneering's research and development efforts and potentially accelerate the delivery of new treatments to patients.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions, which introduces a degree of uncertainty until the deal is finalized.
Key Players & Entities
- Immuneering Corp. (company) — Company filing the report and being acquired.
- Pfizer Inc. (company) — Acquiring company.
- January 13, 2025 (date) — Date of the report and announcement.
- first half of 2025 (date) — Expected closing period for the acquisition.
FAQ
What is the primary reason for Pfizer's acquisition of Immuneering Corp.?
Pfizer is acquiring Immuneering Corp. to enhance its pipeline in immunology and inflammation.
When is the acquisition of Immuneering Corp. by Pfizer expected to close?
The transaction is expected to close in the first half of 2025.
What are the conditions for the closing of the acquisition?
The acquisition is subject to customary closing conditions.
What is Immuneering Corp.'s principal executive office location?
Immuneering Corp.'s principal executive offices are located at 245 Main St., Second Floor, Cambridge, MA 02142.
What is the SEC file number for Immuneering Corp.?
The SEC file number for Immuneering Corp. is 001-40675.
Filing Stats: 541 words · 2 min read · ~2 pages · Grade level 13.2 · Accepted 2025-01-13 16:36:35
Key Financial Figures
- $0.001 — stered Class A common stock, par value $0.001 per share IMRX The Nasdaq Global Market
- $13.7 million — nnounced that it raised net proceeds of $13.7 million in January 2025, through utilization of
Filing Documents
- imrx-20250113.htm (8-K) — 22KB
- 0001790340-25-000014.txt ( ) — 150KB
- imrx-20250113.xsd (EX-101.SCH) — 2KB
- imrx-20250113_lab.xml (EX-101.LAB) — 23KB
- imrx-20250113_pre.xml (EX-101.PRE) — 13KB
- imrx-20250113_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. Recent Developments On January 13, 2025, Immuneering Corporation (the "Company") announced updated interim response and safety data from the ongoing Phase 2a arm evaluating IMM-1-104 with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer patients, part of the Company's ongoing Phase 1/2a clinical trial of IMM-1-104 in patients with advanced RAS-mutant solid tumors. The Company announced that, as of January 6, 2025, of the six evaluable patients in the ongoing Phase 2a arm evaluating IMM-1-104 with mFFX in first-line pancreatic cancer, three patients achieved a partial response (one unconfirmed) and three patients achieved stable disease, collectively representing an interim 50% (3/6) overall response rate (ORR), in each case as measured by RECIST. The three patients that achieved partial responses, and one of the patients that achieved stable disease, remained on treatment. The Company also announced that, as of January 6, 2025, IMM-1-104 in combination with mFFX was observed to be generally well tolerated. On January 13, 2025, the Company also announced that it raised net proceeds of $13.7 million in January 2025, through utilization of the Company's at-the-market equity offering program.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUNEERING CORPORATION Date: January 13, 2025 By: /s/ Michael D. Bookman Name: Michael D. Bookman Title: Chief Legal Officer and Secretary